|Articles|April 7, 2015

YPrime Awarded Global Phase II Oncology Clinical Trial

Author(s)Applied Clinical Trials Editorial Staff

Throughout this trial, YPrime will be supporting world class selected sites to conduct the study with data driven metrics pulled from these tools. YPrime is dedicated to applying its leading edge eClinical technology to help forward unmet medical needs in the Biotech and Pharmaceutical industry.

Y-Prime, Inc., announced it has been awarded an international Phase II clinical trial from a virtual biopharma company to assess a new treatment for patients with Non-Small Cell Lung Carcinoma (NSCLC). This study will be conducted utilizing the company's proprietary eClinical Supply Forecasting tool (eCSF) and Interactive Response Technology (IRT) solution. ClinicalTrials.gov lists the Phase II trials for NSCLC here.

Read the full release.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

Manual protocol translation slows study budgets. AI-enabled automation can shorten the path to negotiations while shifting budget builders to review. Credit: Stock.Adobe.com/7IMJAGO

October 9th, 2026

Start Study Budgets Sooner With AI-Enabled Protocol Translation

AI can turn complex protocols into first-pass budget inputs, letting sponsors start budgeting sooner while budget builders shift from data entry to review.

October 9th, 2026

AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?

Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.

October 9th, 2026

How Routine Lab Markers Can Stand In for Missing Functional Status Data

In this video interview, Carole Berini, PhD, of Ontada, explains how validated proxies for variables like ECOG performance status can recover not just sample size but the representativeness of hard-to-reach patient populations in real-world oncology studies.

Structured data, early assay validation, and broader testing access can move trial matching from retrospective to proactive. Credit: Stock.Adobe.com/wladimir1804.

October 9th, 2026

The Test Is the Ticket: Building Smarter Pathways to Clinical Trial Participation

A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.

October 9th, 2026

ACT Brief: RBQM Analysis Frequency, Building Trust in Oncology Data, and Rare Pediatric PRV Monetization

In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.

© Murrstock - © Murrstock - stock.adobe.com

October 8th, 2026

Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM

Real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis, because signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration.

October 8th, 2026

What It Takes to Harmonize AI Across Fragmented Oncology Health Systems

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation—through source lineage, standardization, and reconciliation—is what makes reliable real-world evidence generation in oncology possible.

October 8th, 2026

ACT Brief: AI and Protocol Design, Site Training Readiness, and GLP-1 Unmet Needs

In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.